135733-31-2Relevant articles and documents
Synthesis of Furoxans (1,2,5-oxadiazole 2-oxides) from Styrenes and Nitrosonium Tetrafluoroborate in Non-Acidic Media and Mechanistic Study
Matsubara, Ryosuke,Ando, Akihiro,Saeki, Yuta,Eda, Kazuo,Asada, Naoki,Tsutsumi, Tomoaki,Shin, Yong Soon,Hayashi, Masahiko
, p. 1094 - 1105 (2016/07/29)
Diverse furoxans (1,2,5-oxadiazole 2-oxides) were synthesized from the corresponding styrenes using nitrosonium tetrafluoroborate as the nitrosation reagent in pyridine (basic media) or dichloromethane (neutral media). Acid-sensitive functional groups were tolerated under these conditions. The probable reaction mechanism was elucidated. The experimental results support an ionic reaction pathway in contrast to the conventional acidic conditions with a radical mechanism.
Synthesis of oxadiazole-2-oxide analogues as potential antischistosomal agents
Rai, Ganesha,Thomas, Craig J.,Leister, William,Maloney, David J.
body text, p. 1710 - 1713 (2009/07/05)
The synthesis of several 1,2,5-oxadiazole-2-oxide (Furoxan) analogues is described herein. These compounds were prepared in an effort to probe the SAR around the phenyl substituent and oxadiazole core for our studies toward thioredoxin-glutathione reductase (TGR) inhibition and antischistosomal activity.
Pharmacochemistry of the furoxan ring: Recent developments
Calvino,Di Stilo,Fruttero,Gasco,Sorba,Gasco
, p. 321 - 334 (2007/10/02)
In the present work recent results obtained in the pharmacochemistry of the furoxan system are reported. In particular, after a brief description of the salient points of the furoxan chemistry, the synthesis and the properties of a series of Nifedipine and Prazosin analogues, containing this heterocyclic system, are described. Since we observed that a few furoxan derivatives are able to elicit both a dose-dependent rise in platelet cGMP levels and to promote a dose-dependent inhibition of AA-induced [Ca++] rise, and that many substituted furoxans show potent vasodilating and antiaggregatory activity, the possibility of using the furoxan system as a lead in the design of new vasodilators is also discussed.